Fusion Antibodies plc
FAB.L · LSE
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | £838 | £758 | £1,207 | £595 |
| % Growth | 10.6% | -37.2% | 102.9% | – |
| Cost of Goods Sold | £653 | £653 | £882 | £651 |
| Gross Profit | £185 | £105 | £325 | -£56 |
| % Margin | 22.1% | 13.9% | 26.9% | -9.4% |
| R&D Expenses | £351 | £15 | £176 | £72 |
| G&A Expenses | £0 | £1,862 | £0 | £2,012 |
| SG&A Expenses | £744 | £917 | £943 | £745 |
| Sales & Mktg Exp. | £0 | -£945 | £0 | -£1,137 |
| Other Operating Expenses | £0 | £158 | £0 | £1 |
| Operating Expenses | £1,095 | £1,090 | £1,119 | £818 |
| Operating Income | -£910 | -£985 | -£794 | -£873 |
| % Margin | -108.6% | -129.9% | -65.8% | -146.7% |
| Other Income/Exp. Net | £362 | £0 | £2 | £4 |
| Pre-Tax Income | -£548 | -£985 | -£792 | -£869 |
| Tax Expense | -£36 | £30 | -£34 | £0 |
| Net Income | -£512 | -£955 | -£758 | -£869 |
| % Margin | -61.1% | -126% | -62.8% | -146.1% |
| EPS | -0.005 | -0.01 | -0.014 | -0.017 |
| % Growth | 54.5% | 27.2% | 20% | – |
| EPS Diluted | -0.005 | -0.01 | -0.014 | -0.017 |
| Weighted Avg Shares Out | 113,210 | 96,396 | 55,556 | 51,026 |
| Weighted Avg Shares Out Dil | 113,210 | 96,393 | 55,556 | 51,026 |
| Supplemental Information | – | – | – | – |
| Interest Income | £2 | £0 | £4 | £1 |
| Interest Expense | £10 | £0 | £2 | £2 |
| Depreciation & Amortization | £62 | £44 | £58 | £94 |
| EBITDA | -£476 | -£888 | -£736 | -£773 |
| % Margin | -56.8% | -117.2% | -61% | -129.9% |